Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Pluton Biosciences tests and discovers microbes for the production of a variety of products, primarily pesticides, and pharmaceuticals.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Capacity Bio is a therapeutics company that is focused on mitophagy.
TeraPore Technologies is a Cornell University spinout that develops and manufactures high performance filters for protein separations.
Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Empatica is an affective computing company focused on human data analytics.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Tasso is a Medical innovation company changing the way diagnostics are delivered
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 22 different industry categories.
Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post Ipo Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Pluton Biosciences, Icosavax, Boundless Bio, Legend Biotech, Ventus Therapeutics. These companies were founded in 2020 or later.